Background
Methods
Objectives
Search strategy
Types of studies
Types of participants
Types of intervention
Types of outcome measures
Risk of bias in included studies
Results
Benzydamine
Chlorhexidine
Reference | Experimental treatment | Control treatment | Duration of follow-up | Method applied to assess cure | Cure rates | Risk ratio (95% CI, p-value) |
---|---|---|---|---|---|---|
Ison 1987 | pessary containing 150 mg chlorhexidine for 2 consecutive nights | single 2 g oral dose of metronidazole
| 7 days | Amsel criteria | 36/43 versus 28/36 | 1.08 [0.86; 1.34], p = 0.5 |
28 days | 14/27 versus 15/25 | 1.16 [0.71; 1.88], p = 0.6 | ||||
Molteni 2004 |
chlorhexidine vaginal gel (2.5 g chlorhexidine per dose) applied for seven days | 500 mg metronidazole vaginal tablet daily for seven days | 28 days | Amsel criteria | 28/30 versus 11/15 | 0.79 [0.57; 1.08], p = 0.06 |
Chaithongwongwatthana 2003 | a single hydrogen peroxide vaginal douche/placebo tablets similar to the metronidazole tablets | 4 tablets of 500 mg metronidazole/placebo vaginal douche with clean water | 14 days | Amsel criteria | 45/72 versus 55/70 | 1.26[1.01; 1.56], p = .036 |
Minozzi 2008 | single dose of 100 ml of a 10% polyhexamethylene biguanide vaginal gel solution | 2% clindamycin cream for 7 days | 21 to 30 days | Amsel criteria and Nugent score | 153/175 versus 143/172 (Amsel) | 0.95 [0.87; 1.04], p = 0.3 |
99/175 versus 99/172 (Nugent) | 1.02 [0.85; 1.22], p = 0.9 |
Dequalinium chloride
Hydrogen peroxide
Octenidine
Polyhexamethylene biguanide
Povidone iodine
Ison 1987 | Molteni 2004 | Chaithongwongwatthana 2003 | Minozzi 2008 | |
---|---|---|---|---|
Random sequence generation |
?
|
+
|
+
|
?
|
Allocation concealment |
?
|
?
|
+
|
?
|
Blinding of participants and personnel |
-
|
-
|
+
|
-
|
Blinding of outcome assessment |
+
|
+
|
+
|
?
|
Incomplete outcome data |
-
|
+
|
+
|
-
|
Selective reporting |
+
|
+
|
+
|
+
|